Details

Autor(en) / Beteiligte

• Douillard, Jean-Yves
• Oliner, Kelly S
• Siena, Salvatore
• Tabernero, Josep
• Burkes, Ronald
• Barugel, Mario
• Humblet, Yves
• Bodoky, Gyorgy
• Cunningham, David
• Jassem, Jacek
• Rivera, Fernando
• Kocákova, Ilona
• Ruff, Paul
• Błasińska-Morawiec, Maria
• Šmakal, Martin
• Canon, Jean Luc
• Rother, Mark
• Williams, Richard
• Rong, Alan
• Wiezorek, Jeffrey
• Sidhu, Roger
• Patterson, Scott D

Titel

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Ist Teil von

• The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other, less common RAS mutations confirms that any RAS mutation is associated with EGFR resistance. KRAS mutation is an established predictive biomarker of resistance to anti–epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer. 1 – 4 Specifically, patients with KRAS mutations in exon 2 do not have a response to anti-EGFR therapy and may have inferior outcomes if this therapy is combined with an oxaliplatin-containing chemotherapy regimen. 2 , 5 More accurate selection of patients according to the genetic status of the tumor may improve the benefit–risk profile of anti-EGFR therapy. Activating mutations in RAS ( KRAS or NRAS ) in addition to KRAS mutations in exon 2 have been suggested as negative predictive biomarkers . . .